University of Missouri School of Medicine MU Health School of Medicine
News Divider

MU Researchers Find Gene Therapy Protects Mice from Heart Condition


The condition is a leading cause of death for those with Duchenne muscular dystrophy

A new gene therapy developed by researchers at the University of Missouri School of Medicine has shown to protect mice from a life-threatening heart condition caused by muscular dystrophy.

Lai

“This is a new therapeutic avenue,” said Yi Lai, PhD, the leading author of the study and assistant research professor in the MU School of Medicine’s Department of Molecular Microbiology and Immunology. “This is just a first step, but we hope this could lead to a treatment for people with this devastating heart condition, which is a leading cause of death for people with Duchenne muscular dystrophy.”

About one in 3,500 children, mostly boys, are born with Duchenne muscular dystrophy (DMD). They experience a progressive wasting away of muscles, starting in the legs and pelvis. Children with DMD have difficulty walking, and most need wheelchairs by age 12.

As DMD depletes the skeletal muscles, it also causes the heart to decay. A weakened heart kills up to 40 percent of people with DMD, usually by their 20s or early 30s. DMD originates with mutations in a single gene. For more than two decades, researchers have explored using gene therapy, an experimental treatment, to replace the flawed gene with a healthy copy.

Duan
Duan

The recent MU study, however, did not try to replace the faulty gene. The researchers targeted a different gene — one involved with the heart’s built-in system for responding to heart attacks and other emergencies.

This targeted gene expresses a protein called nNOS. During short-term stresses, nNOS activates briefly to help regulate the heart. The MU researchers altered the gene to enable more efficient transfer of the nNOS gene to mouse hearts.

Seven months after the gene therapy, the mice who received the treatment showed significantly improved overall heart health. On most disease indicators, the researchers found that the treatment protected their hearts from the damage of DMD.

“The study showed for the first time that a modified nNOS gene could be delivered through gene therapy to protect the hearts of mice from Duchenne muscular dystrophy,” said Dongsheng Duan, PhD, co-author of the study and Margaret Proctor Mulligan Professor in Medical Research at the MU School of Medicine.

“Since nNOS protects against multiple heart diseases, this method could one day be extended to the treatment of other heart diseases, such as heart failure or a heart attack,” Duan said.

The technique is in an early stage of development and will require more research before potential applications in humans are explored.

The study, “Partial Restoration of Cardiac Function with ∆PDZ nNOS in Aged MDX Model of Duchenne Cardiomyopathy,” was published in June in Human Molecular Genetics. Along with Lai and Duan, other study authors include Junling Zhao, research technician, Yongping Yue, senior research specialist, and Nalinda B. Wasala, graduate student, all of the MU Department of Molecular Microbiology and Immunology.

Click here to download a high resolution portrait of Lai.
Click here to download a high resolution portrait of Duan.

 


News and Events

Erika Ringdahl Family Medicine Residency Program
Leader Receives National Award

Ringdahl recognized by American Academy
of Family Physicians for advancing specialty

Zezong Gu, PhD Garlic Found to Protect Brain Against Disease, Aging
Another nod to garlic's reputation as a 'superfood'

Ashley Bartels Research Leads to New Test for Trauma Patients
Resident physician wins first place for clinical science paper

Match Day MU Medical Students in High Demand for Residency Programs
Ninety-nine percent of the class received a residency program match

MU Family Medicine MU Family Medicine Ranked Among Nation’s Best by U.S. News
Top 10 ranking mark of excellence for MU Family Medicine program

Greg Flaker, MD Safer Drug Combination Found For Patients With Atrial Fibrillation.
Newer blood thinner a better option for some patients

Greg Worsowicz, MD Worsowicz Named President-Elect of Medical Society
Organization represents physical medicine and rehab physicians

AAAS MU School of Medicine Launches LCME Re-accreditation Process
Reception kicks off process of accessing medical education program

AAAS Four Scientists Named AAAS
Fellows for Medical Research

Achievements may advance diagnosis
and treatment for patients

Annual Dialysis Conference MU Hosts World’s Largest Dialysis Conference for 35th Year
Event has brought in nearly 65,000 attendees representing 60 countries




Media Relations
University of Missouri Health System
One Hospital Drive, DC028.00
Columbia, MO 65212
24/7 on-call pager: (573) 876-0708

Mary Jenkins
jenkinsmg@health.missouri.edu
(573) 882-7299

Jeff Hoelscher
hoelscherj@health.missouri.edu
(573) 884-1608

Derek Thompson
thompsonder@health.missouri.edu
(573) 882-3323


Web Communications
University of Missouri Health System
One Hospital Drive, MA204G, DC018.00
Columbia, MO 65212
(573) 884-0298

Rich Gleba
glebar@health.missouri.edu
(573) 884-0298

Laura Gerding, APR
gerdingla@health.missouri.edu
(573) 882-9193

Velvet Hasner
hasnerv@health.missouri.edu
(573) 884-1115

Mike Muin
muinm@health.missouri.edu
(573) 884-7541



Printer Friendly
Follow us on Twitter!   Facebook   YouTube Videos   Instagram   Pinterest  
Website created and maintained by the Office of Communications. Contact the MU School of Medicine.
Revised: September 30, 2014 - Copyright © 2014 - Curators of the University of Missouri. All rights reserved. DMCA and other copyright information. An equal opportunity/access/affirmative action/pro-disabled and veteran employer.